Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması
Abstract
Keywords
References
- 1. Böger RH, Ron ES. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev. 2005; 10: 14-23.
- 2. Böger RH. The emerging role of asymmetric dimethyarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003; 59: 824-33.
- 3. Cooke JP. ADMA: its role in vascular disease. Vasc Med. 2005; 10: 11-7.
- 4. Sitar ME, Kayacelebi AA, Beckmann B, Kielstein JT, Tsikas D. Asymmetric dimethylarginine (ADMA) in human blood: effects of extended haemodialysis in the critically ill patient with acute kidney injury, protein binding to human serum albumin and proteolysis by thermolysin. Amino Acids. 2015; 47: 1983-93.
- 5. Teerlink T. ADMA metabolism and clearance. Vasc Med. 2005; 10: 73-81.
- 6. Tain YL, Hsu CN. Toxic Dimethylarginines: Asymmetric Dimethlyarginine (ADMA) and Symmetric Dimethylarginine (SDMA). Toxins (Basel). 2017; 9: 92.
- 7. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl. 2003; 4: 41-51.
- 8. Gwida M, Al Dahouk S, Melzer F, et all. Brucellosis – regionally emerging zoonotic disease? Croat Med J. 2010; 51: 289-95.
Details
Primary Language
Turkish
Subjects
Health Care Administration
Journal Section
Research Article
Authors
Muhammed Sezgin
This is me
0000-0003-2589-9668
Faruk Karakeçili
This is me
0000-0002-7368-7187
Aytekin Çıkman
This is me
0000-0001-9259-7091
Barış Gülhan
This is me
0000-0002-2605-1282
Yusuf Kemal Arslan
This is me
0000-0003-1308-8569
Publication Date
September 16, 2019
Submission Date
March 20, 2019
Acceptance Date
June 20, 2019
Published in Issue
Year 2019 Volume: 46 Number: 3